News

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...
(Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker ...
Eli Lilly & Co. (LLY) shares have come under significant pressure in late May following a pivotal decision by CVS Health's ...
Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...
Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...
Shares of Eli Lilly plunged 11% on Thursday. But several Wall Street analysts said the selloff was overblown. "In our view, the Novo/CVS deal does not represent the beginning of an obesity ...
Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.
Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...
The world’s largest pharmaceutical stock, Eli Lilly and Company LLY, recently had its worst day in a long, long time. On May 1, Lilly reported Q1 earnings. Afterwards, shares got beaten down by ...